Tiotropium Respimat inhaler and the risk of death in COPD
| Data(s) |
17/10/2013
|
|---|---|
| Resumo |
Tiotropium delivered at a dose of 5 μg with the Respimat inhaler showed efficacy similar to that of 18 μg of tiotropium delivered with the HandiHaler inhalation device in placebo-controlled trials involving patients with chronic obstructive pulmonary disease (COPD). Although tiotropium HandiHaler was associated with reduced mortality, as compared with placebo, more deaths were reported with tiotropium Respimat than with placebo. |
| Identificador | |
| Idioma(s) |
eng |
| Direitos |
info:eu-repo/semantics/restrictedAccess |
| Fonte |
Wise , R A , Anzueto , A , Cotton , D , Dahl , R , Devins , T , Disse , B , Dusser , D , Joseph , E , Kattenbeck , S , Koenen-Bergmann , M , Pledger , G , Calverley , P , TIOSPIR Investigators & McGarvey , L 2013 , ' Tiotropium Respimat inhaler and the risk of death in COPD ' New England Journal of Medicine , vol 369 , no. 16 , pp. 1491-501 . DOI: 10.1056/NEJMoa1303342 |
| Palavras-Chave | #Administration, Inhalation #Aged #Aged, 80 and over #Bronchodilator Agents #Double-Blind Method #Female #Forced Expiratory Volume #Humans #Kaplan-Meier Estimate #Male #Middle Aged #Nebulizers and Vaporizers #Pulmonary Disease, Chronic Obstructive #Risk #Scopolamine Derivatives #Spirometry |
| Tipo |
article |
